PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer

BACKGROUND: Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Mineur, L., François, E., Plassot, C., Phelip, J. M., Miglianico, L., Dourthe, L. M., Bonichon, N., Moreau, L., Guimbaud, R., Smith, D., Achille, E., Hervé, R., Bons, J. M., Remy, S., Faroux, R., Villing, A. L., Mahamat, A., Rabbia, I., Soulié, P., Baumgaertner, I., Mathé, N., Vazquez, L., Boustany, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752147/
https://www.ncbi.nlm.nih.gov/pubmed/33347495
http://dx.doi.org/10.1371/journal.pone.0243997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752147/
https://www.ncbi.nlm.nih.gov/pubmed/33347495
http://dx.doi.org/10.1371/journal.pone.0243997

Ejemplares similares